ISSN: 2212-4071 (Online)
ISSN: 1574-891X (Print)
Volume 10, 2 Issues, 2015
Download PDF Flyer
Which Patients have Greatest Need for Elvitegravir/Cobicistat/ Emtricitabine/TenofovirDF-Based Therapy?
Recent Patents on Anti-Infective Drug Discovery, 9
): 41-51.Author(s): Antonio Di Biagio
, Roberta Prinapori
, Lucia Taramasso
, Giulia Gustinetti
, Laura Sticchi
, Bianca Bruzzone
and Claudio Viscoli
InfectiousDiseases Unit, IRCCS A.O.U. San Martino- IST, Genoa, Italy, Largo R. Benzi, 10, 16132 Genoa, Italy.
AbstractElvitegravir/cobicistat/emtricitabine/tenofovirDF (EVG/COBI/FTC/TDF) is the new single-tablet, fixed-dose formulation containing an integrase strand transfer inhibitor recently approved as antiretroviral treatment. In this paper we analysed its use and advantages in naïve and experienced HIV-infected patients and we focused on special populations in which EVG/COBI/FTC/TDF could be a suitable option. Furthermore the manuscript reports the recent patent of EVG which may have an influence on the management of HIV-infected patients in the next future.
Download Free Order Reprints Order Eprints Rights and Permissions